Mobile

Randomized Phase II trial with cetuximab and cisplatin in the treatment of ER negative, PgR negative, HER2 negative metastatic breast carcinoma (“basal-like”)

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005000-13

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess overall response to cetuximab in combination with cisplatin and to show the superiority of the combination over cisplatin alone, in subjects with “triple negative” metastatic breast cancer.

Critère d'inclusion

  • Metastatic breast cancer PR-negative, ER-negative and HER-2 negative

Liens